Pancreatic Cancer Research

ResearcherHospital Universitario La PazActive in the last 2 years

Jaime Feliú

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4867-1420; OpenAlex author ID A5000204001. Sources: OpenAlex.

Their work

Papers
24 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
98
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 5 papers · 2022: 5 papers · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers

Papers 24

  1. CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1. Co-author DOI 10.1016/j.xcrm.2025.102407↗
  2. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. Co-author DOI 10.1158/1078-0432.ccr-23-4026↗
  3. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  4. Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology. Co-author DOI 10.1007/s12094-024-03386-8↗
  5. Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre… Co-author DOI 10.1016/s1470-2045(24)00263-8↗
  6. Cytokines and Pancreatic Ductal Adenocarcinoma: Exploring Their Relationship with Molecular Subtypes and Prognosis. Last author DOI 10.3390/ijms25179368↗
  7. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Co-author DOI 10.1186/s13073-023-01171-w↗
  8. The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic Adenocarcinoma. Last author DOI 10.3390/biomedicines11020252↗
  9. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. Co-author DOI 10.1007/s12094-021-02674-x↗
  10. Neoadjuvant chemotherapy with or without radiotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: a meta-analysis of randomized clinical t… Last author DOI 10.1016/j.esmoop.2022.100485↗
  11. Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors. Co-author DOI 10.3389/fimmu.2022.995715↗
  12. Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Throughput Proteomics. Last author DOI 10.3390/cancers14102414↗
  13. Cytokines and Lymphoid Populations as Potential Biomarkers in Locally and Borderline Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14235993↗
  14. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcino… Co-author DOI 10.1007/s00280-020-04214-w↗
  15. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. Last author DOI 10.1007/s12094-021-02589-7↗
  16. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  17. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Last author DOI 10.3390/cancers13081986↗
  18. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. Last author DOI 10.3748/wjg.v27.i40.6775↗
  19. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  20. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Co-author DOI 10.1038/s41388-019-0803-9↗
  21. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  22. SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). Co-author DOI 10.1007/s12094-016-1586-x↗
  23. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Gru… Co-author DOI 10.1371/journal.pone.0082209↗
  24. Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-010-1472-0↗

Closest collaborators

The 25 strongest of 98 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 11 shared papers, 2016–2025 · strength 1.45
  2. Roberto Pazo-Cid · 6 shared papers, 2022–2025 · strength 0.99
  3. Ismael Ghanem · 6 shared papers, 2021–2024 · strength 0.91
  4. Victoria Heredia-Soto · 4 shared papers, 2021–2024 · strength 0.70
  5. Manuel M. Hidalgo · 5 shared papers, 2020–2025 · strength 0.68
  6. Jean‐Luc Van Laethem · 4 shared papers, 2017–2025 · strength 0.58
  7. Bruno Bockorny · 4 shared papers, 2020–2025 · strength 0.53
  8. Rocio García‐Carbonero · 3 shared papers, 2023–2025 · strength 0.50
  9. Laura Gutiérrez-Sainz · 3 shared papers, 2021–2024 · strength 0.49
  10. Carmen Guillén‐Ponce · 4 shared papers, 2017–2025 · strength 0.49
  11. Emmanuel Mitry · 2 shared papers, 2024–2025 · strength 0.36
  12. Jean‐Frédéric Blanc · 2 shared papers, 2024–2025 · strength 0.36
  13. Hans Prenen · 2 shared papers, 2024–2025 · strength 0.36
  14. Karen Paula Geboes · 2 shared papers, 2024–2025 · strength 0.36
  15. Lorenzo Pilla · 2 shared papers, 2024–2025 · strength 0.36
  16. Aurélien Lambert · 2 shared papers, 2024–2025 · strength 0.36
  17. Philippe Alexandre Cassier · 2 shared papers, 2024–2025 · strength 0.36
  18. Mariano Ponz‐Sarvisé · 3 shared papers, 2020–2025 · strength 0.34
  19. Francesca Sarno · 2 shared papers, 2023–2025 · strength 0.34
  20. Lucía Trilla‐Fuertes · 2 shared papers, 2022–2023 · strength 0.28
  21. Alfredo Carrato · 2 shared papers, 2019–2022 · strength 0.24
  22. M. Guillot Morales · 1 shared paper, 2024 · strength 0.22
  23. Regina Gironés Sarrió · 1 shared paper, 2024 · strength 0.22
  24. Laura Visa · 1 shared paper, 2024 · strength 0.22
  25. Carmen E. Guerra · 1 shared paper, 2025 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.